Allison B Weisbrod1, Mio Kitano1, Francine Thomas2, David Williams2, Neelam Gulati1, Krisana Gesuwan1, Yixun Liu2, David Venzon3, Ismail Turkbey2, Peter Choyke2, Jack Yao2, Steven K Libutti4, Naris Nilubol1, William M Linehan5, Electron Kebebew6. 1. Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Diagnostic Radiology Department, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Biostatistics and Data Management Section, Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. Department of Surgery, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY. 5. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 6. Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kebebewe@mail.nih.gov.
Abstract
BACKGROUND: The incidence of pancreatic neuroendocrine tumors (PNETs) is increasing, but only a subset of these heterogeneous tumors will progress to malignant disease, which is associated with a poor prognosis. Currently, there are limited data on the natural history of these tumors and it is difficult to determine which patients require surgical intervention because the risk of metastatic disease cannot be accurately determined. STUDY DESIGN: We conducted a prospective study of 87 patients with von Hippel Lindau syndrome-associated solid pancreatic lesions to determine the natural history of these tumors with biochemical testing, follow-up anatomic and functional imaging, and advanced imaging analysis, with a median follow-up of 4 years. RESULTS: Approximately 20% of consecutive tumor measurements during follow-up were decreased in size and 20% showed no change. This included 2 of 4 surgically proven malignant tumors, which had a net decrease in tumor size over time. Tumor volume, as derived from greatest diameter and volumetric measurements, showed good correlation to pathology tumor measurement of surgically resected tumors (Spearman rank correlation ρ = 0.72, p = 0.0011, and ρ = 0.83, p < 0.0001, respectively). Tumor density measurement had an inverse relationship with tumor size (Spearman rank correlation -0.22, p = 0.0047). A tumor density cutoff of 200 was 75% specific for malignant tumors. CONCLUSIONS: Pancreatic neuroendocrine tumors demonstrate a nonlinear growth pattern, which includes periods of no growth and apparent decrease in size by imaging. These growth patterns are variable and are not associated with tumor grade and malignancy. Tumor density, as measured in this cohort, may offer a specific diagnostic tool for malignant disease. Published by Elsevier Inc.
BACKGROUND: The incidence of pancreatic neuroendocrine tumors (PNETs) is increasing, but only a subset of these heterogeneous tumors will progress to malignant disease, which is associated with a poor prognosis. Currently, there are limited data on the natural history of these tumors and it is difficult to determine which patients require surgical intervention because the risk of metastatic disease cannot be accurately determined. STUDY DESIGN: We conducted a prospective study of 87 patients with von Hippel Lindau syndrome-associated solid pancreatic lesions to determine the natural history of these tumors with biochemical testing, follow-up anatomic and functional imaging, and advanced imaging analysis, with a median follow-up of 4 years. RESULTS: Approximately 20% of consecutive tumor measurements during follow-up were decreased in size and 20% showed no change. This included 2 of 4 surgically proven malignant tumors, which had a net decrease in tumor size over time. Tumor volume, as derived from greatest diameter and volumetric measurements, showed good correlation to pathology tumor measurement of surgically resected tumors (Spearman rank correlation ρ = 0.72, p = 0.0011, and ρ = 0.83, p < 0.0001, respectively). Tumor density measurement had an inverse relationship with tumor size (Spearman rank correlation -0.22, p = 0.0047). A tumor density cutoff of 200 was 75% specific for malignant tumors. CONCLUSIONS:Pancreatic neuroendocrine tumors demonstrate a nonlinear growth pattern, which includes periods of no growth and apparent decrease in size by imaging. These growth patterns are variable and are not associated with tumor grade and malignancy. Tumor density, as measured in this cohort, may offer a specific diagnostic tool for malignant disease. Published by Elsevier Inc.
Authors: Jane P Ko; Henry Rusinek; Erika L Jacobs; James S Babb; Margrit Betke; Georgeann McGuinness; David P Naidich Journal: Radiology Date: 2003-09 Impact factor: 11.105
Authors: Dag Wormanns; Gerhard Kohl; Ernst Klotz; Anke Marheine; Florian Beyer; Walter Heindel; Stefan Diederich Journal: Eur Radiol Date: 2003-11-13 Impact factor: 5.315
Authors: Helen T Winer-Muram; S Gregory Jennings; Cristopher A Meyer; Yun Liang; Alex M Aisen; Robert D Tarver; Ronald C McGarry Journal: Radiology Date: 2003-10 Impact factor: 11.105
Authors: Ling Zhang; Le Lu; Xiaosong Wang; Robert M Zhu; Mohammadhadi Bagheri; Ronald M Summers; Jianhua Yao Journal: IEEE Trans Med Imaging Date: 2019-09-25 Impact factor: 10.048
Authors: Sven Gläsker; Evelynn Vergauwen; Christian A Koch; Alexander Kutikov; Alexander O Vortmeyer Journal: Onco Targets Ther Date: 2020-06-16 Impact factor: 4.147
Authors: Xavier M Keutgen; Pascal Hammel; Peter L Choyke; Steven K Libutti; Eric Jonasch; Electron Kebebew Journal: Nat Rev Clin Oncol Date: 2016-03-31 Impact factor: 66.675
Authors: Myrthe R Naber; Saya Ahmad; Annemarie A Verrijn Stuart; Rachel H Giles; Gerlof D Valk; Rachel S van Leeuwaarde Journal: J Endocr Soc Date: 2021-12-22